Delving into the Latest Updates on Changchun Haijiya Biotechnology Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Multivalent vaccine

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Multivalent vaccine	1
Prophylactic vaccine	1

1、主要目的初步评价 15μg/亚型/剂四价流感病毒裂解疫苗(0.5ml,预灌封)以全程单剂免疫程序在 3 岁及以上健康人群中接种和 7.5μg/亚型/剂四价流感病毒裂解疫苗（0.25ml,预灌封）以全程两剂（间隔 28 天）免疫程序在 6-35 月龄健康婴幼儿中接种的安全性。 2、次要目的初步评价 15μg/亚型/剂四价流感病毒裂解疫苗(0.5ml,预灌封)以全程单剂免疫程序在 3 岁及以上健康人群中接种和 7.5μg/亚型/剂四价流感病毒裂解疫苗（0.25ml,预灌封）以全程两剂（间隔 28 天）免疫程序在 6-35 月龄健康婴幼儿中接种的免疫原性。

[Translation]

1. Primary objective To preliminarily evaluate the safety of 15μg/subtype/dose quadrivalent influenza virus split vaccine (0.5ml, prefilled) in a full single-dose immunization schedule in healthy people aged 3 years and above, and 7.5μg/subtype/dose quadrivalent influenza virus split vaccine (0.25ml, prefilled) in a full two-dose immunization schedule (28 days apart) in healthy infants and young children aged 6-35 months. 2. Secondary objective To preliminarily evaluate the immunogenicity of 15μg/subtype/dose quadrivalent influenza virus split vaccine (0.5ml, prefilled) in a full single-dose immunization schedule in healthy people aged 3 years and above, and 7.5μg/subtype/dose quadrivalent influenza virus split vaccine (0.25ml, prefilled) in a full two-dose immunization schedule (28 days apart) in healthy infants and young children aged 6-35 months.

Start Date07 Dec 2020

Sponsor / Collaborator

Changchun Haijiya Biotechnology Co., Ltd.

100 Clinical Results associated with Changchun Haijiya Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Changchun Haijiya Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Changchun Haijiya Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Changchun Haijiya Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data